TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)

Biodesix reported Q4 2025 revenue of $28.8 million (41% increase) and full-year revenue of $88.5 million (24% increase), exceeding guidance. Lung Diagnostics revenue grew 47% in Q4 driven by increased test volumes and reimbursement expansion. The company affirmed expectations for positive Adjusted EBITDA in Q4 2025.

Insights
SMCI   neutral

Could see market movement based on Nvidia's AI infrastructure commentary


BDSX   positive

Strong financial performance with 41% Q4 revenue growth and full-year revenue of $88.5M exceeding guidance of $84-86M. Lung Diagnostics segment showed robust 47% growth in Q4 with 23% increase in test volumes. Company affirmed positive Adjusted EBITDA expectations and demonstrated operational leverage. CEO highlighted accelerating growth, expanded reimbursement, and successful clinical data presentations supporting pipeline products.